JBM (Healthcare) (HKG:2161) expects profit attributable to shareholders to increase at least 50% for the six months ended Sept. 30 compared with the corresponding period of the previous year, according to a Friday filing with the Hong Kong bourse.
The company attributed the increase in profit to the robust sales momentum of the group's key brands, notably Ho Chai Kung in the branded medicines segment and Po Chai Pills in the proprietary Chinese medicines segment, supported by the sustained growth of the group's concentrated Chinese medicine granules business.
The company plans to publish its interim results on Nov. 19.
The Medicine company's shares were up about 22% at the close of trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。